Intratumoral Fusobacterium as a prognostic and predictive biomarker in resectable colorectal cancer
Peer-Reviewed Publication
This month, we’re focusing on infectious diseases, a topic that affects lives and communities around the world. Here, you’ll find the latest research news, insights, and discoveries shaping how infectious diseases are being studied, prevented, and treated globally.
Updates every hour. Last Updated: 23-Oct-2026 13:17 ET (23-Oct-2026 17:17 GMT/UTC)
First results from the multicenter FUSOMAP project, led by VHIO, support the potential use of Fusobacterium as a prognostic and predictive biomarker in patients with resectable stage I–III CRC.
Low levels of the amino acid arginine are associated with a number of diseases, including colon cancer. Building on earlier work, researchers have discovered that an arginine-deficient diet stalls the production of the MHC-1 protein, which alerts the immune system to dangers such as a mutating cell or an invading virus. However, increasing arginine levels through diet boosts the number of MHC-I proteins, which suppresses colorectal tumors and enhances immunity to the flu and Covid.
What if cancer screening no longer had to look for one cancer at a time? Cancer screening has long followed a one-organ-at-a-time model: mammography for breast cancer, colonoscopy for colorectal cancer, low-dose CT for lung cancer, and cervical testing for cervical cancer. These programs save lives, but they also leave gaps. Many cancers still lack routine screening, while patients often face multiple appointments, tests, and follow-up procedures.
You may have heard that colorectal cancer is increasingly affecting young adults. However, it is not the only gastrointestinal (GI) cancer that doctors are diagnosing in patients below the age of 50, explains Christina Wu, M.D., an oncologist at Mayo Clinic Comprehensive Cancer Center in Arizona.